Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Julphar
Federal Trade Commission
Chinese Patent Office
Harvard Business School
Johnson and Johnson
Cantor Fitzgerald
Fuji
Mallinckrodt

Generated: June 25, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 091443

« Back to Dashboard

NDA 091443 describes OXYMORPHONE HYDROCHLORIDE, which is a drug marketed by Actavis Elizabeth, Impax Labs, Par Pharm, Specgx Llc, Sun Pharm Inds Ltd, West-ward Pharms Int, Ascent Pharms Inc, Aurolife Pharma Llc, Avanthi Inc, Epic Pharma Llc, and Teva, and is included in thirteen NDAs. It is available from eleven suppliers. Additional details are available on the OXYMORPHONE HYDROCHLORIDE profile page.

The generic ingredient in OXYMORPHONE HYDROCHLORIDE is oxymorphone hydrochloride. There are nine drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the oxymorphone hydrochloride profile page.
Summary for 091443
Tradename:OXYMORPHONE HYDROCHLORIDE
Applicant:Teva
Ingredient:oxymorphone hydrochloride
Patents:0
Therapeutic Class:Analgesics
Formulation / Manufacturing:see details
Pharmacology for NDA: 091443
Mechanism of ActionFull Opioid Agonists
Medical Subject Heading (MeSH) Categories for 091443
Suppliers and Packaging for NDA: 091443
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
OXYMORPHONE HYDROCHLORIDE oxymorphone hydrochloride TABLET;ORAL 091443 ANDA Teva Pharmaceuticals USA, Inc. 0093-5861 N 0093-5861-01
OXYMORPHONE HYDROCHLORIDE oxymorphone hydrochloride TABLET;ORAL 091443 ANDA Teva Pharmaceuticals USA, Inc. 0093-5862 N 0093-5862-01

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength10MG
Approval Date:Feb 15, 2011TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength5MG
Approval Date:Feb 15, 2011TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
QuintilesIMS
Deloitte
US Department of Justice
Teva
Harvard Business School
Boehringer Ingelheim
Queensland Health
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.